News
Video
Approaches to Treatment Decision-Making and Sequencing for HR+, HER2- Metastatic Breast Cancer
Author(s):
The doctors recommend using endocrine therapy-based options first-line when possible, before considering chemotherapy or antibody-drug conjugates, in order to preserve quality of life; they note exceptions could include patients with rapid progression or visceral crisis where immediate chemotherapy may be warranted, and that determining optimal sequencing requires understanding the safety profiles and efficacy data for the available regimens.
EP: 1.An Overview of HR+, HER2- Metastatic Breast Cancer
EP: 2.Overview of the Treatment Landscape for HR+, HER2- Advanced or Metastatic Breast Cancer
EP: 3.The MAINTAIN Trial: Ribociclib in Combination With Endocrine Therapy in Patients With Metastatic Breast Cancer
EP: 4.Approaches to Repeat Hormone Receptor and HER2 Status Testing Before Initiating Later Lines of Therapy
EP: 5.CAPItello-291 Trial: Evaluating Capivasertib Plus Fulvestrant in Patients With HR+, HER2- Advanced Breast Cancer
EP: 6.The EMERALD Trial: Elacestrant in Patients with HR+, HER2- Advanced Breast Cancer
EP: 7.The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer
Now Viewing
EP: 8.Approaches to Treatment Decision-Making and Sequencing for HR+, HER2- Metastatic Breast Cancer
EP: 9.Exciting Ongoing Studies in the Treatment of HR+, HER2- Metastatic Breast Cancer
Related Videos
Related Content
